亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Cancer Therapeutic with Increased Efficacy and Reduced Side Effects

標題: PDK Inhibitor Compounds and Methods of Use Thereof

詳細技術說明: None

*Abstract

Uses Small Drug-Like Molecules to Prevent Cancer Cell Proliferation

This breakthrough approach to treating cancer is efficacious and has limited side effects. Cancer is a leading cause of death in the United States, accounting for one in four deaths annually, according to the American Cancer Society. An estimated 595,600 Americans will die of cancer-related causes in 2016, and predictions for the future continue to rise. Existing treatments often suffer from a lack of efficacy or lead to debilitating side effects for the patient. Researchers at the University of Florida have developed a distinct therapy to specifically target cancerous cell proliferation and halt the growth of tumors and the spread of cancer. This breakthrough treatment also has minimal side effects, making it a desirable treatment for both the patient and health practitioner.

Application

A therapeutic cancer treatment that inhibits the proliferation of cancer

Advantages

Capable of preventing and treating cancer and other cell proliferation diseases, offering a therapy that is effective at a lower concentrations
Decreases cancerous cell proliferation, inhibiting the spread of cancer to other sites and improving the probability of life expectancy
Minimal side effects, improving patient quality of life and providing a significant market advantage

Technology

This technology is a specially designed therapeutic that treats and prevents cell proliferation diseases such as cancer. Small drug-like molecules are used to bind the dichloroacetate (DCA) binding pocket of pyruvate dehydrogenase kinase isoform 2 (PDK2) and inhibit cancer cell proliferation. A patient suffering from or susceptible to a PDK2 mediated disorder or disease is administered a therapeutically effective amount of a compound that activates PDK2 activity, thereby receiving treatment.

*IP Issue Date: Jul 23, 2013

*IP Publication Date: Jan 5, 2012

*Principal Investigation: Name: David Ostrov
Department:

Name: Arun Srivastava
Department:

Name: Peter Stacpoole
Department:

附加資料: Inventor: Charlier, Jr., Henry A. | Gerasimchuk, Nikolay
Priority Number: US7727967B2
IPC Current: A61K003170 | A01N003324 | A01N004304 | A61K003115
US Class: 514034 | 514640
Assignee Applicant: Boise State University,Boise
Title: Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines
Usefulness: Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines
Summary: For improving efficacy of anthracycline cancer treatment (claimed).
Novelty: Pharmaceutical composition for improving efficacy of anthracycline cancer treatment comprises anthracycline compounds and enzyme inhibitors comprising halogenated aryl group

主要類別: 診斷/治療

細分類別: 癌症/腫瘤

申請日期: Jul 1, 2011

申請號碼: 8,492,344

其他

國家/地區: 美國

欲了解更多信息，請點擊這裡